Nathalie Vergnolle
4Patents
1h-index
6Co-inventors
37Inventor score
Filing activity: May 3, 2010 → Sep 22, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9125861B2 | PAR2 agonists for use in the treatment or prevention of influenza virus type A infections | Human Necessities | 1 | Active |
| US9688742B2 | Recombinant probiotic bacteria for the prevention and treatment of inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) | Chemistry; Metallurgy | 1 | Active |
| US10829563B2 | Method of screening a candidate compound for activity as an elastase 2A (ELA2A) inhibitor | Physics | 0 | Active |
| US11692045B2 | Method of treating inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) or gluten hypersensitivity by administering an elastase 2A (ELA2A) inhibitor | Physics | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.